The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

Panelists discuss how chronic graft-vs-host disease (cGVHD) results from complex biological mechanisms involving inflammation, loss of peripheral tolerance, and fibrotic pathways affecting multiple ...

Scientists have discovered that a rare immune cell type in the lungs, called NAMs, plays a crucial role in surviving COVID-19 ...

A rare cell type in the lungs is essential to survival from the COVID-19 virus, a new study shows.

Experiments in mice infected with the SARS-CoV-2 virus revealed that the immune cell class in question, called nerve and ...

In regenerative science, B7-33's potential to influence fibroblast activity and collagen turnover suggests possible implications for tissue repair and wound healing. Given that fibrosis is often a ...

Prof Robert Rintoul discusses a UK Lung Cancer Coalition report and actionable strategies to optimise timely and accurate ...

A comprehensive new review by researchers at the University of Kentucky sheds light on the intricate and damaging ...

According to the American Cancer Society, smoking tobacco is responsible for around 20 percent of all cancer cases and 30 ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, investigators ...